Phaseline

Targets › B3GNT1

B3GNT1 (Beta-1,4-glucuronyltransferase 1): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2029.

Beta-1,4-glucuronyltransferase involved in O-mannosylation of alpha-dystroglycan (DAG1). Transfers a glucuronic acid (GlcA) residue onto a xylose (Xyl) acceptor to produce the glucuronyl-beta-1,4-xylose-beta disaccharide primer, which is further elongated by LARGE1, during synthesis of phosphorylated O-mannosyl glycan. (UniProt, O43505)

Open in Phaseline: the race on B3GNT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Robbie MajznerB7-H3.CD28Z.CART
CAR-T cell therapy targeting B7-H3 with CD28 costimulatory domain
B3GNT1Phase 1Pediatric Solid Tumor; Central Nervous System NeoplasmsDec 2029

Conditions

Pediatric Solid Tumor (1) Central Nervous System Neoplasms (1)

Modalities

mixed (1)

Companies

Robbie Majzner (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.